Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gadopentetate dimeglumine
- Development stage
- Phase 3
- Lead developer
- Bayer
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intraarticular
01
Overview
Gadopentetate dimeglumine is a gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI) to enhance the visibility of blood vessels, organs, and other tissues. It works by altering the magnetic properties of nearby water molecules, thereby improving the contrast of images obtained during MRI scans. Gadopentetate dimeglumine does not cross an intact blood-brain barrier but accumulates in areas where this barrier is disrupted or where there is abnormal vascularity. It is primarily indicated for diagnosing abnormalities in the brain, spine, and other parts of the central nervous system as well as for imaging other body tissues[1][2][3][5]. The drug was originally developed by Schering AG (now part of Bayer). Caution should be exercised in patients with kidney disease due to risk of nephrogenic systemic fibrosis[2].
- Brand names
- Magnevist
- Other names
- gadopentetic acidgadolinium DTPAGd-DTPA
02
Targets
H (Histamine receptors)
Beyond the preview
Go deeper on gadopentetate dimeglumine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gadopentetate dimeglumine.